Investigational HIV Treatment Promising (CME/CE)

Investigational HIV Treatment Promising (CME/CE)
The investigational anti-HIV drug dolutegravir outperformed raltegravir (Isentress) in a randomized trial among patients needing salvage therapy, a researcher said here.

After 48 weeks of therapy, HIV patients who had failed earlier regimens were significantly more likely to control their virus if they were taking dolutegravir, according to Pedro Cahn, MD, of Fundación Huesped in Buenos Aires.